Dublin, May 07, 2026 (GLOBE NEWSWIRE) — The “Panhematin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” has been added to ResearchAndMarkets.com’s offering.
The panhematin market has experienced a notable expansion in recent years and is set for continued growth. By 2026, the market is projected to expand from $2.42 million in 2025 to $2.71 million, at a CAGR of 12.1%. The historical growth is largely due to limited treatment alternatives for porphyria, the availability of orphan drug approvals, usage in hospital emergencies, specialized metabolic disorder centers, and patient advocacy efforts. This momentum is likely to persist with market size reaching $4.24 million by 2030, driven by a CAGR of 11.8%.
The forecast period’s growth can be attributed to improved diagnosis of rare diseases, heightened awareness of acute porphyria, increased access to orphan drugs, supportive reimbursement policies, and the proliferation of specialty care centers. Key trends include the growing use in acute porphyria management, rising prominence of orphan drug treatments, and enhancements in diagnostic awareness and hospital-based emergency therapies for porphyria.
The augmented diagnosis of genetic disorders is a primary driver of the Panhematin market’s growth. With advancements in genetic testing, there is an enhanced capability for early detection and intervention. Panhematin serves as a therapeutic agent for acute porphyrias by providing synthetic heme, alleviating symptoms such as severe abdominal pain and neurological complications. An example reported in April 2023 by the New England Journal of Medicine underscores the identification of genetic causes in approximately 5,500 individuals with severe developmental disorders, highlighting the significance of early diagnosis in driving market growth.
The prevalence of blood disorders, impacting the function or structure of blood cells, is another factor bolstering the Panhematin market. These disorders, driven by genetic, lifestyle, and environmental factors, necessitate specialized treatments, where Panhematin plays a crucial role. Reported by NHS England in May 2024, around 17,000 individuals in England live with sickle cell disease, with Panhematin aiding in mitigating symptoms through restored heme production pathways.
Increased healthcare expenditure is further expected to drive the Panhematin market. Fueled by an aging population, technological advancements, and the demand for quality healthcare, rising expenditures encompass the costs of treating acute porphyria attacks. For instance, the Office for National Statistics reported a 5.6% rise in healthcare expenditure in the UK from 2022 to 2023.
Horizon Therapeutics plc is a key player in the panhematin market. While North America was the leading region in 2025, the Asia Pacific is anticipated as the fastest-growing region in the forecast period, covering regions like Asia-Pacific, Western Europe, Eastern Europe, North America, and more.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $2.71 Million |
| Forecasted Market Value (USD) by 2030 | $4.24 Million |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
Major Trends
- Rising Use in Acute Porphyria Management
- Growth of Orphan Drug Treatments
- Increased Focus on Rare Metabolic Disorders
- Expansion of Hospital Based Emergency Therapies
- Improved Diagnostic Awareness of Porphyria
For more information about this report visit https://www.researchandmarkets.com/r/h0mc9u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
